scholarly article | Q13442814 |
P50 | author | Heike Bickeböller | Q58049828 |
Gerd Hasenfuss | Q61457522 | ||
Anke Krueger | Q112457045 | ||
Michael Pfreundschuh | Q1928879 | ||
Peter Nürnberg | Q2077335 | ||
P2093 | author name string | Markus Loeffler | |
Heike Bickeböller | |||
Jürgen Brockmöller | |||
Albert Rosenberger | |||
Lorenz Trümper | |||
Leszek Wojnowski | |||
Markus Schirmer | |||
Eun-Kyung Suk | |||
Mohammad Reza Toliat | |||
Heidi Hahn | |||
Mladen Tzvetkov | |||
Albrecht Schmidt | |||
Bettina Kulle | |||
Stefan Vonhof | |||
Marita Kloess | |||
Gregor Schlüter | |||
Silvia Seifert | |||
P2860 | cites work | Aldose reductase induction: a novel response to oxidative stress of smooth muscle cells | Q28579062 |
P433 | issue | 24 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | multiple drug resistance | Q643839 |
P304 | page(s) | 3754-3762 | |
P577 | publication date | 2005-12-05 | |
P1433 | published in | Circulation | Q578091 |
P1476 | title | NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity | |
P478 | volume | 112 |
Q36004460 | A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer |
Q37293202 | A discovery study of daunorubicin induced cardiotoxicity in a sample of acute myeloid leukemia patients prioritizes P450 oxidoreductase polymorphisms as a potential risk factor. |
Q54360840 | ABCC1 polymorphism Arg723Gln (2168G> A) is associated with lung cancer susceptibility in a Chinese population. |
Q41709561 | ABCG2 and NCF4 polymorphisms are associated with clinical outcomes in diffuse large B-cell lymphoma patients treated with R-CHOP. |
Q38357704 | Advanced heart failure due to cancer therapy |
Q57302751 | Adverse drug reactions and pharmacogenomics: recent advances |
Q46008254 | Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21. |
Q53128895 | Analyzing the clinical actionability of germline pharmacogenomic findings in oncology. |
Q34639876 | Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment |
Q38542462 | Anthracycline-Induced Cardiomyopathy in Adults |
Q37342407 | Anthracycline-induced cardiotoxicity: prospective cohort study from Pakistan |
Q38025714 | Antineoplastic drug-induced bradyarrhythmias. |
Q92108669 | Antitumour anthracyclines: progress and perspectives |
Q89228158 | Association of CYP2C19*2 and ALDH1A1*1/*2 variants with disease outcome in breast cancer patients: results of a global screening array |
Q94938440 | Association of GSTM1 null variant with anthracycline-related cardiomyopathy after childhood cancer-A Children's Oncology Group ALTE03N1 report |
Q53564509 | Association of NADPH oxidase polymorphisms with anthracycline-induced cardiotoxicity in the RICOVER-60 trial of patients with aggressive CD20(+) B-cell lymphoma. |
Q36804526 | Association of anthracycline-related cardiac histological lesions with NADPH oxidase functional polymorphisms |
Q28478256 | Autophagy inhibition enhances daunorubicin-induced apoptosis in K562 cells |
Q38015746 | Biological drugs: classic adverse effects and new clinical evidences |
Q55208199 | CATCH-KB: Establishing a Pharmacogenomics Variant Repository for Chemotherapy-Induced Cardiotoxicity. |
Q37350809 | CELF4 Variant and Anthracycline-Related Cardiomyopathy: A Children's Oncology Group Genome-Wide Association Study |
Q38313870 | Cancer chemotherapy and cardiac arrhythmias: a review. |
Q38093137 | Cancer pharmacogenomics in children: research initiatives and progress to date. |
Q36887091 | Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues. |
Q33671281 | Candidate Gene Association Studies of Anthracycline-induced Cardiotoxicity: A Systematic Review and Meta-analysis. |
Q38735433 | Cardiac Complications of Cancer Therapy: Pathophysiology, Identification, Prevention, Treatment, and Future Directions |
Q36957758 | Cardiac side effects of anticancer treatments: new mechanistic insights |
Q28068290 | Cardio-Oncology: A Focused Review of Anthracycline-, Human Epidermal Growth Factor Receptor 2 Inhibitor-, and Radiation-Induced Cardiotoxicity and Management |
Q39078275 | Cardio-Oncology: Progress in Diagnosis and Treatment of Cardiac Dysfunction. |
Q49909927 | Cardio-oncology: conflicting priorities of anticancer treatment and cardiovascular outcome |
Q57108766 | Cardio-oncology: protecting the heart from curative breast cancer treatment |
Q39270177 | Cardiotoxicity and cardiomyopathy in children and young adult survivors of hematopoietic stem cell transplant. |
Q33619867 | Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials |
Q41704131 | Cardiotoxicity of cancer chemotherapy: identification, prevention and treatment |
Q88504622 | Cardiovascular Risk in Cancer Survivors |
Q89565308 | Cardiovascular diseases in survivors of childhood cancer |
Q37430831 | Cardiovascular toxicity caused by cancer treatment: strategies for early detection |
Q90415345 | Chemotherapy Related Severe Cardiac Dysfunction - Case Report |
Q39415815 | Chemotherapy-induced cardiotoxicity in children |
Q35222202 | Chemotherapy-induced weakness and fatigue in skeletal muscle: the role of oxidative stress |
Q38231301 | Chemotherapy-related cardiomyopathy: a neglected aspect of cancer survivorship |
Q37390119 | Chronic health conditions in childhood cancer survivors: is it all treatment-related--or do genetics play a role? |
Q37159230 | Clinical and Genetic Determinants of Cardiomyopathy Risk among Hematopoietic Cell Transplantation Survivors |
Q49136273 | Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patients |
Q64900509 | Clinical ascertainment of health outcomes in Asian survivors of childhood cancer: a systematic review. |
Q52928931 | Contraindication labelling changes in the United States and Germany. |
Q38845535 | Current views on anthracycline cardiotoxicity. |
Q37997817 | Disparities in subgroup populations enrolled in lung cancer trials |
Q37834445 | Do pharmacokinetic polymorphisms explain treatment failure in high-risk patients with neuroblastoma? |
Q35048393 | Doxorubicin pathways: pharmacodynamics and adverse effects |
Q35775234 | Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model |
Q92677814 | Doxorubicin-Induced Cardiomyopathy in Children |
Q37998724 | Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies |
Q91620854 | Drug-drug-gene interactions and adverse drug reactions |
Q46987056 | Dystrophin-deficiency increases the susceptibility to doxorubicin-induced cardiotoxicity |
Q51093490 | Effects of ranolazine in a model of doxorubicin-induced left ventricle diastolic dysfunction. |
Q36186203 | Elevated glutathione is not sufficient to protect against doxorubicin-induced nuclear damage in heart in multidrug resistance-associated protein 1 (Mrp1/Abcc1) null mice |
Q90614437 | Ethnogeographic and inter-individual variability of human ABC transporters |
Q88536476 | Evaluation of a polymorphism in MYBPC3 in patients with anthracycline induced cardiotoxicity |
Q41430035 | Evidence for association of SNPs in ABCB1 and CBR3, but not RAC2, NCF4, SLC28A3 or TOP2B, with chronic cardiotoxicity in a cohort of breast cancer patients treated with anthracyclines |
Q40039502 | Exome array analysis identifies ETFB as a novel susceptibility gene for anthracycline-induced cardiotoxicity in cancer patients |
Q28475976 | Flavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol disposition |
Q39337368 | Functional characterization of ABCC2 promoter polymorphisms and allele-specific expression. |
Q39403980 | Functional characterization of protein variants of the human multidrug transporter ABCC2 by a novel targeted expression system in fibrosarcoma cells |
Q93106057 | Genetic Variants Associated With Cancer Therapy-Induced Cardiomyopathy |
Q37167800 | Genetic determinants of drug response in heart failure |
Q34062500 | Genetic polymorphisms in oxidative stress-related genes are associated with outcomes following treatment for aggressive B-cell non-Hodgkin lymphoma |
Q37830057 | Genetic polymorphisms in placental transporters: implications for fetal drug exposure to oral antidiabetic agents |
Q46611556 | Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer |
Q48744224 | Genetic polymorphisms of NAD(P)H oxidase: variation in subunit expression and enzyme activity |
Q37481450 | Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs |
Q37227651 | Genetic susceptibility to anthracycline-related congestive heart failure in survivors of haematopoietic cell transplantation |
Q37271466 | Genetic variants contributing to daunorubicin-induced cytotoxicity |
Q58862883 | Genetic variants inSLC22A17 and SLC22A7are associated with anthracycline-induced cardiotoxicity in children |
Q46169842 | Genome-Wide Association Study for Anthracycline-Induced Congestive Heart Failure |
Q38765132 | Genome-wide association and pathway analysis of left ventricular function after anthracycline exposure in adults. |
Q51816225 | Genome-wide association study of cardiotoxicity in the NCCTG N9831 (Alliance) adjuvant trastuzumab trial. |
Q48171906 | Genome-wide association study of paclitaxel and carboplatin disposition in women with epithelial ovarian cancer |
Q36800903 | Genomic profiling reveals the potential role of TCL1A and MDR1 deficiency in chemotherapy-induced cardiotoxicity |
Q37473789 | Genomics, transcriptional profiling, and heart failure |
Q42727098 | Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma: a pilot study |
Q37614177 | Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer |
Q38868285 | High-sensitive cardiac troponin-I facilitates timely detection of subclinical anthracycline-mediated cardiac injury |
Q36384257 | Higher frequency of genetic variants conferring increased risk for ADRs for commonly used drugs treating cancer, AIDS and tuberculosis in persons of African descent |
Q38874111 | Human Induced Pluripotent Stem Cells as a Platform for Personalized and Precision Cardiovascular Medicine. |
Q35086334 | Hyaluronan synthase 3 variant and anthracycline-related cardiomyopathy: a report from the children's oncology group. |
Q51782486 | Impact of ABC single nucleotide polymorphisms upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia. |
Q33441706 | Impact of NADPH oxidase functional polymorphisms in acute myeloid leukemia induction chemotherapy |
Q38199535 | Importance of ABCC1 for cancer therapy and prognosis. |
Q40670821 | In vitro and in vivo antineoplastic and immunological effects of pterocarpanquinone LQB-118. |
Q36406442 | Individual responses to chemotherapy-induced oxidative stress |
Q46801702 | Induced Pluripotent Stem Cell-Derived Cardiomyocytes: A Platform for Testing For Drug Cardiotoxicity |
Q43253475 | Influence of the polymorphism in candidate genes on late cardiac damage in patients treated due to acute leukemia in childhood |
Q52717628 | Inhibition of TRPA1 Attenuates Doxorubicin-Induced Acute Cardiotoxicity by Suppressing Oxidative Stress, the Inflammatory Response, and Endoplasmic Reticulum Stress. |
Q35913104 | Interindividual variability in hepatic expression of the multidrug resistance-associated protein 2 (MRP2/ABCC2): quantification by liquid chromatography/tandem mass spectrometry |
Q43291060 | Late effects surveillance system after childhood cancer in Germany, austria and parts of Switzerland--update 2009. |
Q34095952 | Limitations in Adjuvant Breast Cancer Therapy: The Predictive Potential of Pharmacogenetics and Pharmacogenomics. |
Q33705877 | Long-term consequences of hematopoietic stem cell transplantation: current state of the science |
Q37023604 | Loss of Mrp1 Potentiates Doxorubicin-Induced Cytotoxicity in Neonatal Mouse Cardiomyocytes and Cardiac Fibroblasts |
Q36186168 | Loss of multidrug resistance-associated protein 1 potentiates chronic doxorubicin-induced cardiac dysfunction in mice |
Q36054324 | Lovastatin protects human endothelial cells from the genotoxic and cytotoxic effects of the anticancer drugs doxorubicin and etoposide |
Q37563014 | Maximizing the Benefit-Cost Ratio of Anthracyclines in Metastatic Breast Cancer: Case Report of a Patient with a Complete Response to High-Dose Doxorubicin. |
Q30439608 | Mechanisms of Anthracycline Cardiotoxicity and Strategies to Decrease Cardiac Damage |
Q42559258 | Mitochondria death/survival signaling pathways in cardiotoxicity induced by anthracyclines and anticancer-targeted therapies |
Q34467407 | Multidrug resistance protein 1 (MRP1, ABCC1), a "multitasking" ATP-binding cassette (ABC) transporter |
Q28468693 | Multidrug resistance-associated protein 1 (MRP1/ABCC1) polymorphism: from discovery to clinical application |
Q35123683 | Multivariable regression analysis of febrile neutropenia occurrence in early breast cancer patients receiving chemotherapy assessing patient-related, chemotherapy-related and genetic risk factors |
Q27001094 | NADPH oxidases in heart failure: poachers or gamekeepers? |
Q37176104 | NOX enzymes as novel targets for drug development |
Q35549037 | National Cancer Institute-National Heart, Lung and Blood Institute/pediatric Blood and Marrow Transplant Consortium First International Consensus Conference on late effects after pediatric hematopoietic cell transplantation: long-term organ damage a |
Q30427656 | Non-invasive imaging and monitoring cardiotoxicity of cancer therapeutic drugs |
Q38112350 | Novel aspects of ROS signalling in heart failure |
Q64269386 | Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity |
Q34322162 | Nox2 NADPH oxidase promotes pathologic cardiac remodeling associated with Doxorubicin chemotherapy |
Q45770434 | Occupational risk assessment of genotoxicity and oxidative stress in workers handling anti-neoplastic drugs during a working week |
Q46253112 | Oxidative Stress and Cellular Response to Doxorubicin: A Common Factor in the Complex Milieu of Anthracycline Cardiotoxicity. |
Q36568908 | Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection. |
Q38876257 | Pathways of cardiac toxicity: comparison between chemotherapeutic drugs doxorubicin and mitoxantrone. |
Q42130469 | Patient-Specific Pluripotent Stem Cells in Doxorubicin Cardiotoxicity: A New Window Into Personalized Medicine |
Q37532571 | Pharmacogenetics in heart failure: promises and challenges |
Q57302675 | Pharmacogenetics of Adverse Drug Reactions |
Q64355486 | Pharmacogenetics of Chemotherapy-Induced Cardiotoxicity |
Q38856218 | Pharmacogenetics of anthracyclines. |
Q37932556 | Pharmacogenetics of genes across the doxorubicin pathway. |
Q38933314 | Pharmacogenetics of irinotecan, doxorubicin and docetaxel transporters in Asian and Caucasian cancer patients: a comparative review. |
Q64077129 | Pharmacogenomic and Pharmacotranscriptomic Profiling of Childhood Acute Lymphoblastic Leukemia: Paving the Way to Personalized Treatment |
Q38887034 | Pharmacogenomics and the treatment of acute myeloid leukemia. |
Q36637796 | Pharmacogenomics as a risk mitigation strategy for chemotherapeutic cardiotoxicity |
Q38688039 | Pharmacogenomics in pediatric acute lymphoblastic leukemia: promises and limitations |
Q27692687 | Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine |
Q36441493 | Pharmacogenomics of drug metabolizing enzymes and transporters: implications for cancer therapy |
Q37305039 | Pharmacogenomics: a tool for improving cancer chemotherapy |
Q38003177 | Pharmacokinetic and pharmacogenetic determinants and considerations in chemotherapy selection and dosing in infants |
Q35034995 | Plasma high sensitivity troponin T levels in adult survivors of childhood leukaemias: determinants and associations with cardiac function |
Q33395469 | Polymorphism in multidrug resistance-associated protein gene 3 is associated with outcomes in childhood acute lymphoblastic leukemia |
Q47137275 | Polymorphisms at microRNA binding sites of Ara-C and anthracyclines-metabolic pathway genes are associated with outcome of acute myeloid leukemia patients |
Q53672562 | Polymorphisms of ABCC5 and NOS3 genes influence doxorubicin cardiotoxicity in survivors of childhood acute lymphoblastic leukemia. |
Q55518023 | Possible roles of genetic variations in chemotherapy related cardiotoxicity in pediatric acute lymphoblastic leukemia and osteosarcoma. |
Q37230408 | Predicting and preventing the cardiotoxicity of cancer therapy |
Q38662111 | Preventing pediatric cardiomyopathy: a 2015 outlook |
Q49037203 | Prevention and Treatment of Cardiac Dysfunction in Breast Cancer Survivors |
Q38838517 | Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity |
Q34774854 | Repositioning of Tyrosine Kinase Inhibitors as Antagonists of ATP-Binding Cassette Transporters in Anticancer Drug Resistance |
Q36921775 | Risk factors for anthracycline-associated cardiotoxicity |
Q60924005 | Role of Endothelium in Doxorubicin-Induced Cardiomyopathy |
Q35327266 | Role of genetic susceptibility in development of treatment-related adverse outcomes in cancer survivors |
Q39454435 | Selenium attenuates adriamycin-induced cardiac dysfunction via restoring expression of ATP-sensitive potassium channels in rats |
Q42678476 | Signalling mechanisms underlying doxorubicin and Nox2 NADPH oxidase-induced cardiomyopathy: involvement of mitofusin-2. |
Q37473480 | Significant dose Escalation of Idarubicin in the treatment of aggressive Non- Hodgkin Lymphoma leads to increased hematotoxicity without improvement in efficacy in comparison to standard CHOEP-14: 9-year follow up results of the CIVEP trial of the D |
Q48143732 | State of the art review: Chemotherapy-induced cardiotoxicity in children. |
Q38606067 | Systems biology approaches to adverse drug effects: the example of cardio-oncology |
Q41313867 | TRPC3 Channels in Cardiac Fibrosis. |
Q35840905 | The G671V variant of MRP1/ABCC1 links doxorubicin-induced acute cardiac toxicity to disposition of the glutathione conjugate of 4-hydroxy-2-trans-nonenal |
Q38200683 | The emerging era of pharmacogenomics: current successes, future potential, and challenges |
Q79536301 | The interleukin-10 gene promoter polymorphism -1087AG does not correlate with clinical outcome in non-Hodgkin's lymphoma |
Q38190105 | The more patients you treat, the more you cure: managing cardiotoxicity in the treatment of aggressive non-Hodgkin lymphoma |
Q52982588 | The role and clinical effectiveness of multimodality imaging in the management of cardiac complications of cancer and cancer therapy. |
Q37734911 | Transgenic expression of the human MRP2 transporter reduces cisplatin accumulation and nephrotoxicity in Mrp2-null mice. |
Q37721782 | Unexpected doxorubicin-mediated cardiotoxicity in sisters: possible role of polymorphisms in histamine n-methyl transferase |
Q34065294 | Urinary coproporphyrin I/(I + III) ratio as a surrogate for MRP2 or other transporter activities involved in methotrexate clearance |
Q34897941 | Urinary elimination of coproporphyrins is dependent on ABCC2 polymorphisms and represents a potential biomarker of MRP2 activity in humans |
Q46409053 | Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children. |
Search more.